Wells Fargo keeps USD 169.00 target for Insmed stock
Published on 10/17/2026 at 22:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and results date
- Wells Fargo maintained its Buy rating and set a USD 169.00 target on October 13, 2026.
- Second-quarter revenue rose 296.10 percent to USD 425.49 million.
- Insmed stock was last quoted at EUR 85.61 at Lang & Schwarz on October 16, 2026 at 11:00 p.m. CEST, with Nasdaq down 2.96 percent versus USD 99.21.
- Insmed reports third-quarter results on October 29, 2026.
Insmed (US4576693075) had its Buy rating maintained by Wells Fargo on October 13, 2026, with a USD 169.00 price target. The target stands 75.50 percent above the Nasdaq close of USD 96.27 on October 16, 2026. The last Lang & Schwarz quote was EUR 85.61 at 11:00 p.m. CEST on October 16, 2026, while the Nasdaq session was down 2.96 percent versus USD 99.21.
Revenue growth changes the scale
Insmed reported second-quarter 2026 revenue of USD 425.49 million, compared with USD 107.42 million a year earlier, a 296.10 percent increase. The company also reported a GAAP net loss of USD 13.24 million, versus a GAAP net loss of USD 321.69 million in the second quarter of 2025, according to Markets Insider.
Stock remains near its yearly low
Insmed traded at USD 96.27 on the Nasdaq on October 16, 2026, against a 52-week range of USD 90.39 to USD 212.75. That places the stock 6.50 percent above its low and 54.75 percent below its high. Volume was 2,395,752 shares, compared with an average volume of 2,603,321 shares.
Valuation and October 29 results
The company had a market capitalization of USD 21.0 billion and a price-to-earnings ratio of minus 23.42 as of October 16, 2026. Insmed's investor calendar lists third-quarter 2026 financial results for October 29, 2026, at 8:00 a.m. EDT, according to Insmed. The company identifies itself as a Nasdaq-listed biopharmaceutical group focused on serious and rare diseases.
Comparison with peers
Insmed (Nasdaq, USD): minus 2.96 percent, P/E minus 23.42, market capitalization USD 21.0 billion
Arcutis Biotherapeutics (Nasdaq, USD): minus 0.96 percent, P/E 138.23, market capitalization USD 3.6 billion
Madrigal Pharmaceuticals (Nasdaq, USD): minus 2.19 percent, P/E minus 34.89, market capitalization USD 10.4 billion
Targets contrast with the price range
Wells Fargo's USD 169.00 target sits well above the latest Nasdaq close, while the stock remains only 6.50 percent above its 52-week low. The October 29 results date is the next scheduled company event.
Insmed was last quoted at EUR 85.61 at Lang & Schwarz on October 16, 2026 at 11:00 p.m. CEST. The Nasdaq closed at USD 96.27 on October 16, 2026, down 2.96 percent from USD 99.21 on October 15, 2026. The further course of trading is shown by the continuously updated real-time quote of Insmed stock.
Insmed market data
- Company: Insmed Incorporated
- ISIN: US4576693075
- Ticker: INSM
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 16, 2026, 11:00 p.m. CEST): EUR 85.61
- Nasdaq session change: minus 2.96 percent versus USD 99.21 on October 15, 2026
- Nasdaq close: USD 96.27 on October 16, 2026
- Market capitalization: USD 21.0 billion (as of October 16, 2026)
- 52-week range: USD 90.39-212.75 (as of October 16, 2026)
- Sector / Industry: Health care / biotechnology
- Next earnings date: October 29, 2026
Market context: Market report Nasdaq Composite.
